NSCLC Videos

Corey Langer, MD, Abramson Cancer Center

Videos

How to Handle Elderly Patients and Individuals With Performance Status 2 and NSCLC

06/14/2023

At the 2023 Great Debates and Updates in Lung Cancer in Chicago, Illinois, Corey Langer, MD, Abramson Cancer Center, University of Pennsylvania, discussed how to best care for the elderly patient population, as well and patients with...

At the 2023 Great Debates and...

06/14/2023

Oncology

Kim Norris, Lung Cancer Foundation of America

Videos

Understanding and Employing Patient Advocacy

05/16/2023

At the 2023 Great Debates and Updates conference in Chicago Illinois, Kim Norris, co-founder and president of the Lung Cancer Foundation of America, discussed the different types of patient advocacy and the effect advocacy can have on...

At the 2023 Great Debates and...

05/16/2023

Oncology

Edward Garon, MD, University of California Los Angeles

Videos

Frontline Management of NSCLC After Approval of Durvalumab Plus Tremelimumab and Chemotherapy

12/22/2022

Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss options for frontline management of NSCLC after the most recent approval of durvalumab plus tremelimumab and chemotherapy based on results from the POSEIDON trial.

Edward Garon, MD, and Lyudmila...

12/22/2022

Oncology

Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute

Videos

How to Handle Patients With PD-L1 >50% Non-Small Cell Lung Cancer

12/13/2022

Leena Gandhi, MD, PhD, discusses the debate held at the 2022 Great Debates and Updates in Lung Cancer meeting, addressing first-line treatment options for patients with non-small cell lung cancer and PD-L1 > 50%.

Leena Gandhi, MD, PhD, discusses...

12/13/2022

Oncology

Mark Awad, MD, PhD, Dana-Farber Cancer Institute

Videos

Overcoming Resistance to Checkpoint Inhibitors in Lung Cancer

12/13/2022

Dr Mark Awad reviews his presentation at the 2022 Great Debates and Updates in Lung Cancer meeting in New York which focused on the management of patient resistance to checkpoint inhibitors.

Dr Mark Awad reviews his...

12/13/2022

Oncology

Videos

Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC

06/03/2020

Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with NSCLC.

Solange Peters, MD, PhD,...

06/03/2020

Oncology

Videos

Recent Advancements in the Treatment of HER2+ NSCLC

06/01/2020

Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.

Solange Peters, MD, PhD,...

06/01/2020

Oncology

Videos

Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC

06/01/2020

Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.

Yasir Elamin, MD, talks about...

06/01/2020

Oncology

Videos

Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC

05/31/2020

Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.

Yasir Elamin, MD, talks about...

05/31/2020

Oncology

Videos

Experts Identify Mutational Biomarker for Poor Prognosis in ALK+ NSCLC

05/30/2020

David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.

David Carbone, MD, PhD, comments...

05/30/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology